Nuvalent (NUVL) Other Non-Current Liabilities (2024 - 2026)

Nuvalent's (NUVL) quarterly Other Non-Current Liabilities came in at $35000.0 in Q4 2025, down 75.0% on a QoQ basis from $140000.0 in Q3 2025.

Analysis

Nuvalent (NUVL) Other Non-Current Liabilities (2024 - 2026) Analysis & Trends

Nuvalent (NUVL) has 2 years of Other Non-Current Liabilities data on file, last reported at $35000.0 in Q4 2025.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $35000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35000.0 (changed N/A YoY) and the FY2025 annual result came in at $35000.0, changed N/A from the prior year.
Other Non-Current Liabilities fell to $35000.0 in Q4 2025, from $140000.0 in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $16.6 million in Q3 2024 to a low of $35000.0 in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Nuvalent	9.75 Bn	9.75 Bn	-

Historic Data

Download Data